Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING NA

Assessment of the GORE® EXCLUDER® Conformable AAA Endoprosthesis in the Treatment of Abdominal Aortic Aneurysms

NCT02489539 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of the study is to assess the safety and effectiveness of the GORE® EXCLUDER® Conformable AAA Endoprosthesis to treat an infrarenal aneurysm located in the abdominal aorta. Performance of the GORE® EXCLUDER® Conformable AAA Endoprosthesis will be judged by separate performance goals.

Conditions Studied

Interventions

  • DEVICE GORE® EXCLUDER® Conformable AAA Endoprosthesis

Study Locations (20)

Florida

  • River City Clinical Research — Jacksonville
  • Baptist Cardiac and Vascular Institute — Miami
  • Florida Hospital — Orlando
  • Sarasota Vascular Specialists — Sarasota

Minnesota

  • Essentia Institute of Rural Health — Duluth
  • Minneapolis Heart Institute Foundation - Abbott Northwestern Hospital — Minneapolis
  • Minneapolis Radiology and Vascular Research Foundation — Plymouth
  • Mayo Clinic - Rochester — Rochester

California

  • University of Southern California — Los Angeles
  • Leland Stanford Junior University — Stanford

Georgia

  • Emory University — Atlanta
  • Vascular Surgical Associates, PC — Marietta

Illinois

  • Loyola University - Chicago — Maywood
  • Southern Illinois University — Springfield

Michigan

  • University of Michigan — Ann Arbor
  • Spectrum Health System — Grand Rapids

Alabama

  • University of Alabama at Birmingham — Birmingham

Arizona

  • Mayo Clinic Arizona — Phoenix

Trial Details

FieldValue
Enrollment Target 175 participants
Start Date 2017-12-19
Est. Completion 2027-12-31
Phase NA

Sponsor

W.L.Gore & Associates

117 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02489539

The ClinicalTrials.gov registry entry for NCT02489539 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 175 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is W.L.Gore & Associates, which has 117 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Aortic Aneurysm, Abdominal appearing as the primary indexed condition, and to 1 intervention — of which GORE® EXCLUDER® Conformable AAA Endoprosthesis is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT02489539 reports 20 study locations spanning 10 distinct geographic areas — top geographies include Florida, Minnesota, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT02489539 about?

NCT02489539 is a clinical study titled "Assessment of the GORE® EXCLUDER® Conformable AAA Endoprosthesis in the Treatment of Abdominal Aortic Aneurysms". The purpose of the study is to assess the safety and effectiveness of the GORE® EXCLUDER® Conformable AAA Endoprosthesis to treat an infrarenal aneurysm located in the abdominal aorta. Performance of the GORE® EXCLUDER® Conformable AAA Endoprosthesis will be judged by separate performance goals.

What is the current status of trial NCT02489539?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 175 participants. The study started on 2017-12-19. Estimated completion is 2027-12-31.

What conditions does trial NCT02489539 study?

This clinical trial studies the following conditions: Aortic Aneurysm, Abdominal. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT02489539?

The interventions under investigation include: GORE® EXCLUDER® Conformable AAA Endoprosthesis (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT02489539?

This trial is sponsored by W.L.Gore & Associates, which has 117 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT02489539 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial